| CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies (NCT07763938) | The First Affiliated Hospital with Nanjing Medical University | 2026-11-01 |
| A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies (NCT07628582) | The First Affiliated Hospital with Nanjing Medical University | 2026-09-15 |
| Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies (NCT07493174) | Institute of Hematology & Blood Diseases Hospital, China | 2026-04-15 |
| Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies (NCT07345728) | Donghua Zhang | 2026-01-01 |
| IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies (NCT07309900) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2025-11-21 |
| Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies (NCT07240974) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2025-10-28 |
| The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies (NCT07002112) | The First Affiliated Hospital with Nanjing Medical University | 2025-05-23 |
| UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies (NCT06590961) | Ubix Therapeutics, Inc. | 2025-02-20 |
| A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies (NCT05780034) | Accutar Biotechnology Inc | 2023-06-20 |
| A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies (NCT04861779) | Haisco Pharmaceutical Group Co., Ltd. | 2021-08-24 |
| CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies (NCT04943016) | National Taiwan University Hospital | 2021-07-01 |
| This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies (NCT04689308) | Minghui Pharmaceutical (Shanghai) LTD | 2021-01-07 |
| Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects (NCT02825836) | Telios Pharma, Inc. | 2016-08-26 |
| Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies (NCT02457559) | Gilead Sciences | 2015-09-10 |